Genetic control of RAV-O production in chickens.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to E J Smith.
Explore the source record for details and available documents.
Two transplant patients suffered Candida infections after receiving homografts from a cadaveric donor whose urine culture yielded Candida albicans greater than 100,000 colonies per ml. In both patients the infections became apparent after large doses of methylprednisolone were administered for acute rejection. Flucytosine proved to be inadequate therapy but modified doses of amphotericin B served to eradicate the infection in each case. Donor urine cultures yielding Candida albicans should be interpreted as representing a transmissible infection.
Explore the source record for details and available documents.
This investigation was designed to compare detection limits for avian leukosis viruses after infection of chicken fibroblasts with decimal dilutions of Rous-associated virus type 1 (RAV-1). At 5, 9, 14, and 19 days postinfection, cells were examined for group-specific (gs) antigens by microtiter complement-fixation (CF) tests for avian leukosis viruses and by radioimmunoassays (RIA) for the major gs antigen having a molecular weight of 27,000 (p27). Culture fluids, collected at the same time periods, were also assayed for reverse transcriptase activities. We found that minimally infected cultures expressed virus proteins within 9 days postinfection regardless of method used. Although p27 RIA was consistently more sensitive than CF or reverse transcriptase assays, sensitivity was only two- to fivefold greater when concentrated suspensions of RAV-0, RAV-1, and RAV-2 were compared. In terms of infectious units, the lowest detectable virus titer was 6 X 10(3) infectious units as determined by RIA end point dilutions. However, our results led us to conclude that when concentrated cell extracts are tested with hamster antiserum, CF is adequate for detecting infection.
Detailed analysis of the clinical data and autopsy material of 100 consecutive renal transplant recipients revealed significant thromboembolic disease in 25 patients and a total of 41 complications. In six of them, thromboembolism was associated with sepsis. Nine patients died (20% of total number of deaths) due to a primary thromboembolic event. The incidence of pulmonary embolism was 14%; myocardial infarction, 3%; cerebrovascular disease, 4%; renal artery thrombosis, 2%; renal vein thrombosis, 3%; thrombophlebitis/deep vein thrombosis, 13%; and miscellaneous, 2%. The incidence of thromboembolism was higher in patients older than 40 years of age (P = .02) and during the earlier months after transplantation. We summarize the general incidence and mortality related to thromboembolism and discuss the factors predisposing the graft recipient to thromboembolic disease. Prevention and therapy of this complication should decrease the morbidity and mortality in graft recipients and enhance the success of renal transplantation.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Radioimmunoassays were developed for the 19,000, 15,000, and 12,000 molecular weight polypeptides of avian myeloblastosis virus and for the 19,000 and 12,000 polypeptides of RAV-0, a subgroup E avian tumor virus. Each polypeptide was shown to possess both group- and type-specific antigenic determinants, in contrast to the 27,000 mol wt polypeptide, which contained only group-specific determinants. The corresponding low-molecular-weight polypeptides of subgroup A, B, and E viruses were shown to be immunologically indistinguishable. The findings that low-molecular-weight polypeptides of subgroup C and D viruses reacted very differently in immunoassays for the respective polypeptides of avian myeloblastosis virus or RAV-0 suggest that subgroups C and D may have evolved differently form subgroups A, B, and E.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.